Annals of clinical and translational neurology · 2026
Disease Course After Anti-CD20 Discontinuation in Secondary Progressive Multiple Sclerosis-A Multicenter Long-Term Longitudinal Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Otto Ferdinand, Kliushnikova Dariia, Radlberger Richard Friedrich, Yasaroglu Sinan, Moser Tobias, Harrer Andrea, Kratzer Kitty, Hitzl Wolfgang, Gradl Christiane, Schmidauer Martin, Roth Patrick, Hegen Harald, Wipfler Peter
Аннотация
OBJECTIVE: To describe long-term outcomes after anti-CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease-modifying therapy (DMT).
METHODS: We retrospectively analyzed data from four centers in Austria and Switzerland. Inclusion criteria were SPMS, ≥ 2 anti-CD20 cycles, discontinuation without subsequent DMT, and ≥ 36 months follow-up. The primary endpoint was time to first confirmed Expanded Disability Status Scale (EDSS) worsening, defined as a ≥ 0.5-point increase after discontinuation documented at a subsequent routine visit. Secondary endpoints were relapses, MRI activity, and severe infections. No continuation cohort was available.
RESULTS: Fifty-five patients were included (61% female). Mean age at anti-CD20 start was 53.5 ± 6.6 years, disease duration 19.3 ± 10.1 years, treatment duration 32.8 ± 16.1 months, and post-discontinuation follow-up 55.1 ± 14.1 months. Mean EDSS increased from 5.9 ± 1.3 before anti CD20, to 6.3 ± 1.3 at discontinuation and 6.9 ± 1.2 at last follow-up. Confirmed EDSS worsening occurred in 31 patients (56%). Hazard analysis suggested an exploratory late increase between 48 and 60 months (p = 0.043) based on small numbers at risk. Relapses occurred in 6 patients (10.9%), MRI activity in 4/35 (11%), and severe infections in 17 (31%).
CONCLUSIONS: In this selected SPMS cohort, focal inflammatory activity was uncommon, whereas confirmed EDSS worsening accumulated over long-term follow-up. Because inclusion required ≥ 36 months untreated follow-up, early disease activity may have been underestimated, and apparent stability may have been overestimated. Findings are descriptive and hypothesis-generating and do not establish safety or optimal timing of anti-CD20 discontinuation.
METHODS: We retrospectively analyzed data from four centers in Austria and Switzerland. Inclusion criteria were SPMS, ≥ 2 anti-CD20 cycles, discontinuation without subsequent DMT, and ≥ 36 months follow-up. The primary endpoint was time to first confirmed Expanded Disability Status Scale (EDSS) worsening, defined as a ≥ 0.5-point increase after discontinuation documented at a subsequent routine visit. Secondary endpoints were relapses, MRI activity, and severe infections. No continuation cohort was available.
RESULTS: Fifty-five patients were included (61% female). Mean age at anti-CD20 start was 53.5 ± 6.6 years, disease duration 19.3 ± 10.1 years, treatment duration 32.8 ± 16.1 months, and post-discontinuation follow-up 55.1 ± 14.1 months. Mean EDSS increased from 5.9 ± 1.3 before anti CD20, to 6.3 ± 1.3 at discontinuation and 6.9 ± 1.2 at last follow-up. Confirmed EDSS worsening occurred in 31 patients (56%). Hazard analysis suggested an exploratory late increase between 48 and 60 months (p = 0.043) based on small numbers at risk. Relapses occurred in 6 patients (10.9%), MRI activity in 4/35 (11%), and severe infections in 17 (31%).
CONCLUSIONS: In this selected SPMS cohort, focal inflammatory activity was uncommon, whereas confirmed EDSS worsening accumulated over long-term follow-up. Because inclusion required ≥ 36 months untreated follow-up, early disease activity may have been underestimated, and apparent stability may have been overestimated. Findings are descriptive and hypothesis-generating and do not establish safety or optimal timing of anti-CD20 discontinuation.